Marina Biotech this week announced that it has established an early-stage research collaboration with an undisclosed "major pharmaceutical company" focused on the evaluation of Marina's proprietary amphoteric liposomal formulations for pulmonary delivery.
Additional details about the arrangement were not disclosed.
Marina also said that the Intellectual Property Office of New Zealand has issued a notice of acceptance for a company patent application related to tumor-targeting delivery peptides.